Morgan Stanley downgraded Erasca (ERAS) to Equal Weight from Overweight with a price target of $2, down from $4. The firm sees better opportunities in the space after Erasca announced its fifth reprioritization with plans to seek a strategic partner to further develop naporafenib. The company is not expected to report initial clinical data until 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS: